BackgroundTreatment of prostate cancer often involves androgen deprivation therapy (ADT) by gonadotropinâreleasing hormone (GnRH) receptor agonists, GnRH receptor antagonists, or orchiectomy. ADT may increase the rate of cardiovascular disease events, but recent clinical studies suggested that not all means of ADT carry the same risk, raising the possibility of nonâtestosteroneâmediated effects of different forms of ADT on atherosclerosis. Here we compared effects of ADT on atherosclerosis in intact and orchiectomized Apoeâdeficient mice.Methods and ResultsChowâfed Apoeâdeficient mice were allocated to orchiectomy and/or monthly injections with the GnRH receptor agonist leuprolide or the GnRH receptor antagonist degarelix. Atherosclerosis was quantified at 26Â weeks of age in the aortic arch by en face examination and in the aortic root by histology. In intact Apoeâdeficient mice, all types of ADT reduced testosterone production to castration levels. Although hypercholesterolemia was accentuated in leuprolideâtreated mice, the amount and composition of atherosclerosis was not different between the different types of ADT. In orchiectomized Apoeâdeficient mice, leuprolide, but not degarelix, augmented hypercholesterolemia, changed body, thymus, and spleen weights, and increased atherosclerosis in the aortic root. No direct effects of the drugs were detectable on cytokine secretion from murine bone marrowâderived macrophages or on splenocyte proliferation.ConclusionsNo differences in the development of atherosclerosis were detected among groups of intact Apoeâdeficient mice treated with different types of ADT. A proâatherogenic, possibly cholesterolâmediated, effect of leuprolide was seen in orchiectomized mice that might be relevant for understanding the potential cardiovascular risk associated with GnRH agonistâbased ADT.